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ORIGINAL ARTICLE

Evaluation of trained immunity by β-1, 3 (D)-glucan
on murine monocytes in vitro and duration of response
in vivo
Pablo Garcia-Valtanen1, Ruth Marian Guzman-Genuino1, David L Williams2, John D Hayball1,3
and Kerrilyn R Diener1,3
The β-1, 3 (D)-glucan (β-glucan) present in the cell wall of Candida albicans induces epigenetic changes in human monocytes
resulting in primed macrophages exhibiting increased cytokine responsiveness to reinfection. This phenomenon is referred to as
trained immunity or innate immune memory. However, whether β-glucan can reprogramme murine monocytes in vitro or induce
lasting effects in vivo has yet to be elucidated. Thus, puriﬁed murine spleen-derived monocytes were primed with β-glucan
in vitro and assessed for markers of differentiation and survival. Important macrophage cell markers during monocyte-tomacrophage differentiation were downregulated and survival enhanced due to partial inhibition of apoptosis. Increased survival
and not the β-glucan training effect explained the elevated production of tumour necrosis factor-α (TNFα) and interleukin-6
(IL-6) induced by subsequent lipopolysaccharide (LPS) challenge. In vivo, 4 days after systemic administration of β-glucan, mice
were more responsive to LPS challenge as shown by the increased serum levels of TNFα, IL-6 and IL-10, an effect shown to be
short lived as enhanced cytokine production was lost by day 20. Here, we have characterised murine macrophages derived from
β-glucan-primed monocytes based on their surface marker expression and for the ﬁrst time provide evidence that the training
effect of β-glucan in vivo declines within a 3-week period.
Immunology and Cell Biology (2017) 95, 601–610; doi:10.1038/icb.2017.13

Trained immunity was coined to describe the ability of the innate arm of
the mammalian immune system to activate mechanisms by which
immune cells, after a ﬁrst pathogen insult, increase their ability to protect
against reinfection from the same or different pathogen.1,2 While trained
immunity has long been known to operate in invertebrate,1 vertebrate3–8
and plant species,9 it is only in recent years that the molecular
mechanisms that lead to trained immunity in mammalian cells have
been described. These studies have focused mainly on natural killer
cells6,10,11 and monocytes.8,12,13 For instance, binding of the surface
receptor dectin-1 to the pathogen-associated molecular pattern (PAMP)
β-1, 3 (D)-glucan (β-glucan),14 commonly present on the cell wall of
fungi, has been shown to trigger epigenetic reprogramming in human
monocytes mainly through changes in histone trimethylation at
H3K4.8,13 Macrophages derived from these β-glucan-primed monocytes
(BG-Mφ) exhibit a degree of training or memory and respond with
increased release of inﬂammatory cytokines to subsequent infections
with related or unrelated pathogens.2,8,12,13,15–19
The bulk of the data on the in vivo effects of β-glucan in murine
models has been generated mainly in experiments carried out with
Candida albicans organisms. Mice treated with sublethal strains of
1

C. albicans are partially or totally protected against a subsequent
infection with lethal strains of C. albicans, C. tropicalis or, more
importantly, the unrelated pathogenic bacterium Staphylococcus aureus
up to 14 days after C. albicans exposure.19 This protection was
mediated by the plastic-adherent population of mouse splenocytes,
and resulted in a number of circulating polymorphonuclear leucocytes, including monocytes, remaining elevated in the blood for up to
20 days.19 This protection has been shown to be accompanied by
epigenetic changes in peritoneal macrophages and act independently
of adaptive immunity.8,16
While sublethal C. albicans infections have provided a valuable means
to study trained immunity in murine models, the extent of the speciﬁc
contribution of β-glucan to the activation of trained immunity in vivo
and the length of its effect still remains poorly understood. Moreover,
the in vivo effects of β-glucan cannot be inferred from experiments
where whole C. albicans have been used to induce trained immunity as
C. albicans-infected animals are inherently exposed to other foreign
microbial components. For instance, chitin from the
cell wall of C. albicans enhances resistance to anti-fungal agents,20 and
is also a potent trained immunity activator.21 Similarly, other
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Figure 1 In vitro differentiation of murine and human monocytes after the addition of serum to cell culture media. Murine (top panels) and human
monocytes (bottom panels) were isolated, treated and cultured following the schedule indicated in the timeline diagram (bottom), with images captured at
day 0 (untreated) and 5 days later after priming with LPS, β-glucan or RPMI. All pictures were taken using the same magniﬁcation objective (×40), and are
representative of six others.

components of the cell wall of C. albicans exert immunosuppressive
functions during infection in murine models.22,23 These are likely to
mask or enhance β-glucan-induced effects in vivo and in vitro, including
its ability to induce trained immunity. Furthermore, in previous studies
where puriﬁed β-glucan was used to activate trained immunity in vivo,
its effects beyond 7 days after its administration were not detailed;12,15,17
thus, it is difﬁcult to unequivocally ascertain whether the in vivo
responses to infection in animals pretreated with β-glucan are exclusively the result of lasting innate immune memory (i.e., trained
Immunology and Cell Biology

immunity) or a combined response due to the overlap of the innate
responses to both β-glucan and the subsequent immune challenge.
In this study, we investigated the ability of C. albicans-puriﬁed
β-glucan to prime murine spleen-derived monocytes in vitro. We
found that the differentiation of monocytes after a priming period
with β-glucan produced large cells with a morphology consistent with
macrophages and lower expression levels of the cell surface markers
F4/80, CD11b, CD11c and MHC II, relative to control Mφ.
Subsequent stimulation of BG-Mφ with lipopolysaccharide (LPS)
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Figure 2 β-Glucan-trained macrophages express relatively low levels of phagocytic cell surface markers. Undifferentiated monocytes (Mo, day 0) or
differentiated macrophages (day 7) were collected and stained with antibodies against CD11b, F4/80, MHC II and CD11c and subsequently assessed by ﬂow
cytometry. (a) Representative histogram plots showing the expression of the different cell surface markers in undifferentiated Mo (day 0) or day 7
differentiated macrophages initially primed with β-glucan (black), LPS (grey) or RPMI (white, control). (b) Percentage of positive cells for each of the four
markers evaluated in monocytes and differentiated macrophages. Spleen monocytes from ﬁve mice were analysed in independent experiments for all makers.
Bars and error bars represent average and s.e.m. values, respectively. * and **P-values ⩽ 0.05 and 0.01, respectively.

resulted in enhanced secretion of tumour necrosis factor-α (TNFα)
and interleukin-6 (IL-6); however, this could be largely explained
by a greater number of cells surviving in culture over a 6-day period,
a ﬁnding that was recapitulated in human peripheral blood
mononuclear cell (PBMC)-derived monocytes. Moreover, increased
survival of murine monocytes coincided with a relative reduction in
apoptosis after β-glucan treatment. In vivo, β-glucan-trained mice
challenged with LPS 4 days later resulted in increased production of
TNFα, IL-6 and IL-10 serum cytokines, a response not seen after
20 days, suggesting that the β-glucan priming effect in vivo is not
sustained beyond 3 weeks in adult mice and therefore suggesting that
β-glucan-mediated trained immunity is transitory.

were subjected to a differentiation process driven by the addition of
normal murine or human serum to the cell cultures using the same
protocol as described previously5 (see timeline in Figure 1). Irrespective of the primary stimulus, all cell treatment groups underwent
profound morphological changes by day 5 of the assay. In both cases
(mouse and human), round-shaped monocytes (day 0) differentiated
into cells with increased size, and often elongated morphology on day
5, with all exhibiting a classical mature macrophage morphology
irrespective of their origin. Whereas differences in morphology among
treatments was not as prominent in the murine assays, human cells
treated with LPS or β-glucan (LPS-Mφ and BG-Mφ) were generally
larger than control cultured macrophages (Mφ) (Figure 1).

RESULTS
Splenic monocytes primed with β-glucan in culture differentiate
into macrophage-like cells
Since β-glucan has only been shown to induce trained immunity in
human monocytes in vitro, puriﬁed murine splenic monocytes or
human PBMC-derived monocytes were cultured with β-glucan, LPS
or cell culture media alone for 24 h. To ensure that results were
comparable to previous published studies, puriﬁed β-glucan was
obtained from the same source, produced in the same laboratory
using the same methodology.5,13 After an initial priming period, cells

Splenic monocytes primed with β-glucan express relatively low
levels of macrophage markers upon differentiation
Recent studies have found that β-glucan exposure inﬂuences the cell
surface marker phenotype of human BG-Mφ,5,13 but, to date,
the expression of macrophage-relevant surface markers on murine
BG-Mφ has not been studied. Therefore, puriﬁed naïve splenic
monocytes (day 0) and Mφ after LPS challenge (day 7) were stained
with antibodies against CD11b to assess whether the expression of
this marker, highly expressed in mouse splenic monocytes,24 was
modulated as a result of the differentiation process. Additionally, the
Immunology and Cell Biology
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cells were stained with anti-CD11c and anti-F4/80 antibodies to
evaluate whether the differentiated cells adopted a predominantly
dendritic cell or macrophage phenotype, respectively. Finally,
MHC class II expression was investigated to evaluate the antigenpresenting ability of the differentiated cells. As expected, monocytes on
day 0 expressed high levels of CD11b and low expression of F4/80,
MHC II or CD11c (Figure 2a).24 After priming and differentiation,
the number of CD11b-expressing cells decreased in LPS-Mφ and
Mφ from 93% to 52% and 55%, respectively, with the decrease more
pronounced in BG-Mφ cultures (93–26%) (Figure 2b). Differentiation
increased the expression of F4/80 by 99% and 10% in LPS-Mφ and
Mφ cultures, respectively, while expression in BG-Mφ decreased by
55% when compared with the initial expression levels in naïve
monocytes. Similarly, MHC II was upregulated on the surface of
LPS-Mφ and Mφ (from 88% on day 0 to 24 and 25%, respectively),
but slightly decreased in BG-Mφ (6%). All treatments resulted
in the downregulation of CD11c; however, BG-Mφ exhibited the
lowest expression (o1% of the cells were CD11c positive). Median
intensity ﬂuorescence values for all marker and treatment groups are
summarised in Supplementary Table 1.
Priming with β-glucan results in increased cell viability in murine
and human monocytes in vitro
During cell surface marker analysis, the number of live singlet cells
identiﬁed by FSC-weight/FSC-height and SSC-weight/SSC-height
gating and lack of DAPI (4',6-diamidino-2-phenylindole) staining
(see gating strategy; Supplementary Figure 1a) exhibited considerable
variability depending on the initial priming stimulus. On day 7 in all
murine assays, BG-Mφ were more abundant than LPS-Mφ or control
Mφ (Figure 3a), despite initial cell numbers being variable between
individual mice (Supplementary Table 2). This suggested that β-glucan
may have facilitated the survival of differentiating monocytes during
the culture period. To determine whether these observations were also
true for human blood monocytes treated with β-glucan, similar
analyses were performed. As it was possible to isolate more monocytes
per volunteer than per mouse, the number of live cells at day 1 after
the priming period, and day 6 after the differentiation period, was
evaluated. On day 1, live β-glucan-treated monocytes were more
abundant than control monocytes, as were those cultured with LPS
(Figure 3b). This early difference in cell numbers was sustained
during the differentiation phase, as on day 6, after monocytes had
differentiated into macrophages, BG-Mφ numbers were still signiﬁcantly higher than control Mφ. Moreover, monocyte cultures from
volunteers 1, 3 and 6 also proliferated in the ﬁrst 24 h in response to
β-glucan (Supplementary Table 2). Taken together, these results
suggest that stimulation with β-glucan has a prosurvival effect on
monocytes from both human and mouse.
To further investigate how β-glucan may facilitate survival of
murine monocytes in vitro, the level of apoptosis was evaluated at
different time points during the differentiation period. For this,
puriﬁed murine monocytes were stained on days 0, 1 and 4 of culture
with Annexin V (AnnV) and propidium iodide (PI). On day 1, after
the priming period and before initiation of the differentiation period,
the percentage of AnnV+PI+ (i.e., late apoptotic and/or necrotic) in the
β-glucan-treated cultures was consistently lower than that of the LPS
and control groups (quadrants Q2 in Figures 3c and d), and not
different to that observed at day 0 before culture. In contrast, more
than 50% of LPS-treated and control cells were AnnV+PI+ after the
priming period (Figure 3d). Dot plots suggested that cultured
monocytes ﬁrst became apoptotic, and then proceeded to a late
apoptotic/secondary necrotic phenotype within this time. This was
Immunology and Cell Biology

conﬁrmed by staining cells for the expression of caspase-3/7, effector
caspases present in late stages of cell apoptosis processes,25 which
indicated to different extents, positive caspase-3/7 staining in all
treatment groups (Supplementary Figure 1b). Interestingly, the
proportion of monocytes at different stages of apoptosis during
this 24 h period was not the same for each treatment group.
Cultures treated with β-glucan exhibited an increased proportion of
live (AnnV−PI−) cells at the start of the differentiation period
(Figure 3e), and an increased percentage of AnnV+PI− cells, generally
indicative of cells in early apoptosis, at the same time point (Figure 3f).
Taken together, this suggested that β-glucan slowed the rate at which
monocytes entered the apoptosis pathway, thus leaving these cultures
at the start of the differentiation period with a larger number of viable
AnnV−PI− cells in comparison with LPS or control treatment. It is also
possible that a proportion of the AnnV+PI− cells may not actually be
apoptotic but rather bind AnnV due to translocation of phosphatidylserine to the outer membrane as part of processes related to
membrane receptor selection, as has been previously described for B
cells,26 and therefore contribute to the elevated numbers of DAPI−,
live cells in this group (Figure 3a). By day 4 all treatments showed low
numbers of AnnV+PI+, indicating that the cells that initially survived
went on to differentiate into macrophages (Figure 3d).
Increased survival of β-glucan-treated monocytes dictates the
amount of TNFα or IL-6 released in response to LPS
BG-Mφ derived from human monocytes has been shown to induce
epigenetic changes resulting in the secretion of increased amounts of
TNFα and IL-6 after stimulation with LPS.5,8,12,13 By using the same
protocols and source of β-glucan, we have recapitulated this increased
cytokine production here in human monocytes (Figure 4a). In
a similar manner, murine BG-Mφ cultures challenged with LPS
resulted in a 2.0- and 3.6-fold increase in TNFα and IL-6 compared
with LPS-Mφ and Mφ (Figures 4c and e, respectively). However, when
total cytokine data was normalised by the number of live cells detected
per well in each treatment, the previous difference in TNFα and IL-6
cytokine expression was negated (Figures 4d and f). Surprisingly,
normalising human TNFα expression to the number of viable human
monocytes per treatment also resulted in the same effect (Figure 4b),
indicating that BG-Mφ release of inﬂammatory cytokines is, to
a certain extent, affected by β-glucan-induced survival in both species,
mouse and human.
Enhanced cytokine responses in β-glucan-trained mice declines
within 3 weeks
Since our in vitro results did not unequivocally answer the question of
whether murine BG-Mφ exhibit higher sensitivity to subsequent LPS
challenge, and since all reports to date only show trained immunity
effects in mice in vivo within a four to seven day window, the effects
of β-glucan in vivo was more comprehensively assessed. For this,
C57Bl/6 J mice were systemically administered two 1 mg doses of
β-glucan as described previously.12,17 Control mice were injected with
isovolumetric endotoxin-free phosphate-buffered saline (PBS). Then,
at 4 days (short-term) or 20 days (long-term) after β-glucan
administration, mice were challenged in vivo with LPS and the
serum levels of TNFα, IL-6 and IL-10 measured 2.5 h after challenge
(see timeline; Figure 5a). In the short-term experiment, serum
cytokine levels in trained mice (β-glucan-treated) were signiﬁcantly
higher for TNFα (5.7-fold), IL-6 (2.4) and IL-10 (3.1) in comparison
with PBS-treated mice (Figure 5b). Control mice in the long-term
experiment exhibited similar cytokine production levels after LPS
stimulation at 20 days to that of control mice in the short-term
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Figure 3 β-Glucan facilitates the survival of differentiating monocytes in vitro. (a) Fold change in live cells (normalised against control cells) after priming,
differentiation and LPS challenge (day 7) in the murine in vitro assays (n = 6), and (b) healthy volunteers (n = 8) on days 1 and 6 under the same culture
conditions and treatments. (c) Dot plots representing the apoptotic status of murine monocytes on day 0 (untreated) and treated monocytes on day 1. Cells
were stained with FITC-conjugated AnnV and PI. Late apoptotic and/or necrotic cells are gated in the top right quadrant of each of the dot plots (AnnV+PI+).
(d) Combined AnnV+PI+ data, (e) AnnV−PI− data and (f) AnnV+PI− data obtained from three independent experiments at different time points during the
differentiation assays. Bars and error bars represent averages and s.e.m., respectively. * and **P-values ⩽ 0.05 and 0.01, respectively.

experiment (Figure 5c). However, in contrast to trained mice in the
short-term experiment, trained mice did not exhibit signiﬁcantly
increased serum cytokine levels, indicating a loss of heightened
inﬂammatory responses to endotoxemia within a 3-week period.
DISCUSSION
The present study describes the in vitro effects of β-glucan priming on
macrophages (BG-Mφ) derived from monocytes isolated from the
spleen of C57Bl/6 J mice as well as its effect in vivo after administration

by intraperitoneal injection. We found that β-glucan partially
protected cultured monocytes from apoptosis and this, in turn, led
to both increased cell numbers and secreted inﬂammatory cytokine
levels after challenge with LPS. In vivo, we demonstrated that the
heightened response of β-glucan-trained mice to endotoxemia only
ensues when β-glucan is administered a few days before LPS challenge,
providing evidence that the trained phenotype might be transient.
Monocytes act as a myeloid precursor reservoir of tissue-resident
macrophages and antigen-presenting dendritic cells.27 In vitro, in the
Immunology and Cell Biology
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Figure 4 Increased survival of β-glucan-trained macrophages determines increased TNFα and IL-6 levels in vitro. (a) Total and (b) live cell number
normalised amount of TNFα released into cell supernatants by human macrophages after challenge with 10 ng ml − 1 of LPS. (c) Total and (d) normalised
murine TNFα released into supernatants. (e) Total and (f) normalised IL-6 was measured in the same supernatants. *P-values ⩽ 0.05.

presence of serum, human blood monocytes differentiate into
macrophages after a few days in culture. Moreover, if primed with
β-glucan the resulting macrophages (BG-Mφ) exhibit increased
responsiveness to bacterial PAMPs such as LPS.5,8,12,13 Using β-glucan
from the same source and laboratory and identical experimental
procedures as previous human studies, murine monocytes, in the
presence of mouse serum, differentiated from small round monocytes
into large elongated cells consistent with macrophage or dendritic
cell morphology. This differentiation also occurred irrespective of
the priming stimulus- (LPS or β-glucan) producing cells with similar
morphology.
At the molecular level, priming with β-glucan induces epigenetic
reprogramming that leads to, among other changes, a phenotype of
human BG-Mφ that exhibits a distinct surface marker proﬁle.5 In
murine BG-Mφ originated from splenic monocytes, the expression of
F4/80 in BG-Mφ was signiﬁcantly lower than that of LPS-Mφ and
control Mφ, suggesting that the initial β-glucan stimulus blocks or
inhibits the expression of F4/80. The marker F4/80 is highly expressed
in macrophages from different murine tissues.28 By contrast, murine
peritoneal macrophages infected with Bacillus Calmette-Guerin (BCG)
express signiﬁcantly lower levels of F4/80 than their non-infected
counterparts.29 Similarly to β-glucan, BCG was found to induce
epigenetic changes in monocytes that lead to trained immunity.30
Our results indicate that downregulation of F4/80 in BG-Mφ as well as
Immunology and Cell Biology

in BCG-infected Mφ could be a shared trait among certain trained
macrophage phenotypes. Additionally, β-glucan downregulated the
expression of MHC II, whereas BCG vaccination upregulates
this marker in macrophages.29 BCG, a whole-cell pathogen-based
vaccine, is known to induce antigen presentation31,32 and lead
to the development of long-lasting protective immunity against
Mycobacterium tuberculosis.33 Puriﬁed β-glucan is a single PAMP
among the many expressed in the cell wall of fungal species and,
therefore, is not likely to favour an antigen-presenting cell function,
at least not to the same extent as BCG. On the other hand,
downregulation of CD11c in BG-Mφ suggests that β-glucan steers
the monocyte differentiation process away from dendritic cell-like
phenotypes and functions, which include antigen-presenting functions
and could partially explain why MHC II is also downregulated.
Similarly to the previous makers, CD11b (a cell surface integrin),
highly expressed in naïve monocytes, was markedly downregulated in
BG-Mφ. This integrin is directly involved in facilitating the function of
pattern recognition receptors such as TLR334 and TLR4,35 which
sense the PAMPs polyinosinic:polycytidylic acid (poly I:C) and LPS,
respectively. Thus, downregulation of CD11b could inﬂuence the
ability to respond to such PAMPs, and perhaps other stimuli, and
modulate the immune function of BG-Mφ. In contrast with our
results in mice, human BG-Mφ have been shown to upregulate
CD11b, compared with control Mφ.5 Differences in the expression of
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Figure 5 The enhanced in vivo response in β-glucan-trained mice declines in the ﬁrst 3 weeks. (a) Timeline of the β-glucan dosage schedule in the murine
in vivo experiments. (b) Serum levels of TNFα, IL-6 and IL-10 in β-glucan- or PBS-treated mice in the short-term experiment and (c) in the long-term
experiment. At least nine mice per group and two independent experiments were performed in all cases. Horizontal and error bars represent average and
s.e.m. values. * and ***P-values ⩽ 0.05 and 0.001, respectively.

this receptor in BG-Mφ among different species might determine the
magnitude of subsequent responses to PAMPs, and therefore their
ability to resolve secondary infections in immune trained organisms.
The ﬂow cytometric analysis of each individual mouse experiment
showed a relatively increased survival in BG-Mφ during the monocyteto-macrophage differentiation period, compared with LPS-Mφ and
Mφ, and this was also evident with human blood monocytes.
Consistent with enhanced cell viability, the percentage of dead
apoptotic cells after the priming period was signiﬁcantly lower in
the β-glucan-treated monocyte cultures. In culture, monocytes and
other short-lived immune cells rapidly undergo apoptosis in a process
mediated by long non-coding RNA in the absence of soluble factors
such as granulocyte–macrophage colony-stimulating factor, IL-3 or
IL-5.36 This is consistent with high apoptosis-mediated cell death seen
in control (not primed) as well as LPS-treated monocytes. On day 4,
low levels of dead apoptotic cells were observed in all groups,
presumably because the necessary soluble factors had been released
and accumulated in the supernatants during this period of time. In
line with these results, several in vivo studies have shown that
treatment with β-glucan (from C. albicans and other sources) or a
sublethal C. albicans infection can increase the number of tissueresident and blood polymorphonuclear leucocytes in different murine
species15,17,19 and in cancer patients.37 In vivo, however, we believe
that apoptosis due to lack of soluble factors is less likely to occur since
a larger number of cell types are present in most organs and can,
potentially, be the source of such soluble factors. Thus, more research

is needed to determine whether the in vitro assay to investigate
monocyte trained immunity-like responses described here and in
previous studies5,8,12,13,21 provides an accurate reﬂection of these
responses in vivo.
One of the key characteristics of the human trained BG-Mφ
phenotype is its increased ability to release proinﬂammatory cytokines
in response to subsequent challenges with PAMPs and whole
pathogens,5,8,12,13 results that were recapitulated in this study using
peripheral blood monocytes from healthy volunteers. This increase in
inﬂammatory cytokines (TNFα and IL-6) was also observed in
supernatants from murine BG-Mφ in response to LPS. However,
having observed that β-glucan priming resulted in increased cell
survival, we reanalysed the cytokine data taking this into account.
Interestingly, when total cytokine release data was normalised by the
number of live cells per well in each treatment, no differences between
BG-Mφ and the control groups (LPS- Mφ and Mφ) were observed. In
both species the enhanced inﬂammatory response of BG-Mφ appeared
to be a reﬂection of the increased Mφ numbers available to respond to
LPS. Based on our results we believe that to different extents, other
studies that did not account for the increased number of cells in
culture due to treatment with β-glucan5,8,12,13 might have overestimated the capacity of these cells to release inﬂammatory cytokines
in vitro.
A week after systemic β-glucan administration to mice, TNFα and
IL-6 were signiﬁcantly increased in trained mice after challenge with
LPS. Using the same time frame and dose of β-glucan, others have
Immunology and Cell Biology
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subsequently demonstrated that such trained mice are more resistant
to infection with the pathogenic bacterium S aureus.12,15 However, in a
longer experiment, we demonstrated that mice that had received the
same dose of β-glucan 20 days before challenge with LPS did not
show increased serum cytokine responses. Therefore, on the one
hand, our short-term experiments (in combination with previous
studies12,15) strongly suggest that after a few days of systemic
administration of β-glucan, the murine immune system is more
efﬁcient in responding to LPS. Similarly, TNFα and IL-6 serum levels
are signiﬁcantly elevated in mice trained with heat-inactivated
C. albicans 7 days before challenge with LPS.8 On the other hand,
the long-term experiment showed that serum TNFα and IL-6 in
trained mice fell to PBS-injected control mice levels, suggesting that
the murine-trained phenotype might be transient or rapidly changing
in its ability to elicit inﬂammatory responses. Similarly, after a rapid
increase in blood polymorphonuclear leucocytes and monocytes and
spleen cellularity caused by systemic administration of a sublethal
strain of C. albicans, these cell numbers declined by day 20 after
stimulation with C. albicans.19 Thus, the decline in cytokine production observed in trained mice at 20 days post-treatment and previous
studies that show that a decline in monocytes occurs at the same time
point after identical treatment19 suggest that increases in cytokine
production in trained mice could be linked to, at least to an extent, to
increases in cell numbers, presumably monocyte/macrophage cells.
We also provided evidence that in vitro this is likely to be the
mechanism that results in higher readouts of inﬂammatory cytokines
in BG-Mφ. Additionally, serum IL-10 was also increased in trained
mice in the short-term experiment, but when measured in the in vitro
training experiments, this cytokine was not present at detectable levels
(data not shown). This suggests that increased serum IL-10 levels
in vivo are produced by cells other than BG-Mφ to control exacerbated
inﬂammatory responses in trained mice. Conversely, in the long-term
experiments, where the inﬂammatory response (TNFα and IL-6) to
endotoxemia was similar in trained and control mice, IL-10 serum
levels were also similar, which further supports the hypothesis that the
β-glucan effect does not persist in the trained mice.
Taken together, these results open an interesting question about the
duration and nature of trained immunity mediated by β-glucan in
murine models. Often, trained immunity is described as the memory
of the innate immune system.2,18 In fact, trained immunity phenotypes that share traits with the β-glucan-trained phenotype, such as
that generated by the BCG vaccine, seem to have long-lasting effects in
humans.3,7 Based on our in vivo cytokine results and previous reports
that studied changes in immune cell numbers in vivo after stimulation
with β-glucan,19 it could be argued that the training effect of
β-glucan peaks at around 2 or 3 weeks after its administration.
β-glucan-induced trained immunity relies on epigenetic changes8,12,13
and the duration of the innate immune memory might be limited by
the lifespan and turnover of the trained cell population (i.e., BG-Mφ).
It is expected that future studies looking at the long-term effects of
β-glucan on the innate immune system, such as this one, will provide
the basis to form a more accurate picture of how trained immunity is
induced and affects the immune response to secondary infections in
murine models. In vivo challenge experimental models to test the
ability of the murine β-glucan-trained phenotype to survive infection
will be key to provide answers to these questions.
METHODS
Animals
Male C57Bl/6 J (6–8 weeks) mice were bred in-house at the Reid Animal
Facility, University of South Australia, and housed in individually ventilated
Immunology and Cell Biology

cages under standard speciﬁc-pathogen free conditions with food and water
provided ad libitum. All animal experiments were carried out with dual
approval from the University of South Australia and The University of Adelaide
Animal Ethics Committees, and conducted in accordance with National and
Institutional ethical and regulatory guidelines.

Antibodies and cell staining reagents
The antibodies APC-anti-mouse/human CD11b (BioLegend, San Diego, CA,
USA; cat. no. 101212), Alexa Fluor 488-anti-mouse MHC II (I-Ab) (BioLegend;
cat. no. 116410), biotin-anti-mouse CD11c (BioLegend; cat. no. 117303),
streptavidin-APC-Cy7 (BD, San Jose, CA, USA), anti-mouse CD16/32, that is,
Fc block, (eBioscience, San Diego, CA, USA; cat. no. 14-0161-86), PE-antimouse F4/80 (eBioscience; cat. no. 12-4801-82) and DAPI (4′,6-diamidino-2phenylindole; Sigma-Aldrich, St Louis, MO, USA) were used in cell staining
assays.

Monocyte isolation and stimulation experiments
A commercial kit of antibody-conjugated magnetic beads was used to negatively
select and isolate naïve monocytes from the spleens of C57Bl/6 mice. Isolation
was carried out according to the instructions provided by the manufacturer.
Cells consistent with both monocyte morphology (as described elsewhere) and
high CD11b and low CD11c, Ly71 and MHC II (I-Ab) surface expression were
obtained.24 Then, monocytes were resuspended in RPMI cell culture medium
(Sigma-Aldrich) supplemented with 2 mM L-glutamine, 10 mM HEPES,
12 μg ml− 1 penicillin and 16 μg ml − 1 gentamycin (the Media Production Unit
at the Royal Adelaide Hospital) and allowed to adhere to the bottom of the
wells in 96-well plates for 1 h at 37 °C. After this period, the media were
removed and replaced with 100 μl of the same supplemented culture medium
(control cells), medium containing 5 μg ml − 1 of β-glucan (from C. albicans38)
or 100 ng ml − 1 of LPS (E. coli strain 0111:B4; Sigma-Aldrich). After 24 h, the
treatments were washed away with prewarmed (37 °C) RPMI media and
replaced with 150 μl RPMI in the same supplemented culture medium
containing 10% mouse pooled sera. Then, cells were allowed to differentiate
in the wells for 5 days. After the differentiation period, cell culture media
were removed and cells were challenged by adding supplemented culture
medium containing 10 ng ml − 1 of LPS. At 24 h after the challenge with LPS,
supernatants were collected for cytokine assessment by Bead Array Assays
(mouse) or Enzyme-linked Immunosorbent Assays (human) and cells were
harvested for cell surface marker staining and analysis.
For the human in vitro assays, PBMCs were isolated from blood from
healthy volunteers using Lymphoprep (StemCell Technologies, Vancouver,
BC, Canada) standard procedures. Then, PMBCs were plated in 96-well plates
at a density of 5 × 105 cells per well in a total volume of 100 μl in supplemented
RPMI media and incubated at 37 °C. After 1 h, the cells were washed three
times with prewarmed PBS (37 °C) to eliminate non-adherent cells. The
remaining cells were used in the stimulation protocols as described above.
Human PBMC-derived monocytes were also consistent with monocyte
morphology and high CD11b expression (data not shown). Images
of the monocytes were taken using Olympus IX51 ﬂuorescence microscope
(Olympus Corporation, Tokyo, Japan) and processed using the software
cellSens Entry v.1.13 (Olympus Corporation).

Cell surface marker staining and analysis by ﬂow cytometry
On day 7 in the in vitro murine assays and days 1 and 6 in the human
assays, cells were collected for cell surface marker staining and posterior
analysis by ﬂow cytometry. Brieﬂy, cells were incubated with Tryple Select
(100 μl per well), an enzymatic disassociation reagent, for 10 min at room
temperature. Under the conditions used here, Tryple Select did not have any
effect in the amount of positive cells or intensity of marker-associated
ﬂuorescence for any of the markers analysed in this study (Supplementary
Figure 2). Immediately after this, cells were resuspended in 2 ml of
PBS containing 2% FBS (FACS staining buffer), spun down at 300 g for
5 min at 4 °C and resuspended again in 100 μl FACS staining buffer containing
2.5 μg ml − 1 of anti-mouse CD16/32 (Fc block). After a 15 min incubation at
4 °C, 100 μl of FACS staining buffer containing 1 μg ml − 1 of anti-mouse
CD11b, 10 μg ml − 1 of anti-mouse CD11c, 1 μg ml − 1 of anti-mouse Ly71,
1.25 μg ml − 1 anti-mouse MHC II (I-Ab) and 1 μg ml − 1 DAPI was added to
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each tube and the mixes were incubated for 20 additional minutes at 4 °C.
Then, 2 ml of FACS staining buffer were added to all samples and each tube
was spun down at 300 g for 5 min at 4 °C. Finally, cells were resuspended in a
10% neutral-buffered formalin solution and kept in the dark at 4 °C until
analysed. The same protocol was used for human monocytes. These cells were
stained anti-human 1 μg ml − 1 CD11b and 1 μg ml − 1 DAPI.
Flow cytometric data acquisition was carried out in BD FACSAria Fusion
(BD). Flow cytometric data was analysed using the software FlowJo v.10.0.7
(FlowJo, LLC, Ashland, OR, USA).

Mouse cytokine detection by bead array-based detection methods
A Bead Array Kit (custom LEGENDplex panel; BioLegend) was used to detect
TNFα, IL-6 and IL-10 based on sandwich ELISA principles. Cytokine
concentration was determined using standard curves obtained using recombinant cytokine standards provided in the kit. Bead signal readouts were obtained
using the ﬂow cytometer BD FACSAria Fusion (BD).

Human TNFα detection by ELISA
Human TNFα was evaluated using recombinant TNFα (ELISA standard)
(BioLegend), LEAF Puriﬁed anti-human TNFα (BioLegend), biotin-antihuman TNFα (BioLegend), streptavidin-HRP (horse radish peroxidase;
Rockland, Limerick, PA, USA) and SIGMAFAST OPD (o-phenylenediamine
dihydrochloride) tablets (Sigma-Aldrich). Brieﬂy, high-binding 96-well plates
were coated with 50 μl of the capture antibody and kept at 4 °C overnight. After
washing, the wells were blocked with 200 μl of 2% bovine serum albumin-PBS
for an hour. Samples and standards were incubated in the wells for 3 h and
then detected using 50 μl of the biotin-conjugated antibodies. Streptavidin-HRP
antibodies were added after washing. The presence of cytokines was visualised
using OPD tablets as a colorimetric substrate for HRP. The plates were then
read at 490 nm using the MultiSkan FC (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) plate reader.

received 1 mg of β-glucan in each injection. In the short-term experiment,
blood was obtained from the facial vein of the mice on day 1 to assess for
pre-existing levels of TNFα, IL-6 and IL-10 in the serum. On day 0, all mice
were challenged intraperitoneally with 400 μl of a solution containing 250 ng of
LPS in PBS. At 2.5 h after challenge, blood from each mouse was obtained
by cardiac bleeding and collected in MiniCollect Z serum Sep tubes
(Greiner Bio-One, Kremsmünster, Austria) for serum separation by centrifugation. Serum samples were stored at − 20 °C until used.

Statistical analysis
Graphs and statistical analysis were carried out using the GraphPad Prism6
(GraphPad Software, La Jolla, CA, USA). Murine in vitro apoptosis data was
compared using analysis of variance (Fisher’s least signiﬁcant difference test) for
multiple comparisons. Three independent experiments were performed with
cells from a total of four mice. The Wilcoxon's rank test (paired data,
one-tailed) was used to analyse the in vitro cytokine and cell number data
obtained in both murine and human assays. In the in vitro assays, ﬁve to six
mice were assayed in four independent experiments and blood from eight
donors were assayed in three independent experiments.
In the in vivo assays, nine to ten mice were used in all groups in both the
short- and long-term experiments. The Friedman test (paired data, one-tailed)
was used to analyse the murine in vitro cell marker data. In these assays, ﬁve
mice were assayed in three independent experiments for each of the cell
marker. The degree of statistical signiﬁcance and sample size is indicated in
each ﬁgure.
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Normalisation of in vitro TNFα and IL-6 results
In the human experiments, PBMCs from each volunteer were seeded as
described above in four different plates corresponding to day 0, 1, 6 and 7.
At each time point, cells were harvested and stained with DAPI. Counts for
DAPI-negative cells (live cells) were used to obtain live cell numbers at the
different time points (Supplementary Table 2). Day 6 live cell numbers were
used to normalise the secreted TNFα values in human assays. Similarly,
day 7 data were used to normalise TNFα values obtained in the murine assays.
DAPI ﬂuorescence and cell counts were evaluated by ﬂow cytometry. For
normalisation, the following formula was used in both murine and human
assays:


Normalised TNFa pg ml1 ¼ TNFa pg ml1 =½live cells perwell=1000

Evaluation of apoptosis in murine monocytes
Apoptosis and cell death was assessed using the The ApoDETECT Kit
(Life Technologies, Carlsbad, CA, USA) and analysed by ﬂow cytometry.
Brieﬂy, cells were stimulated following the same procedure as in the stimulation
experiments. On day 0 (before stimulation), day 1 (24 h after stimulation) and
day 4 (3 days into the differentiation period) cells were harvested and incubated
with 3 μl AnnV-FITC in binding buffer for 10 min, and then washed and
resuspended in binding buffer before the addition of 2 μl of PI (20 μg ml − 1).
Cells were recorded as early apoptotic (AnnV+PI − cells), late apoptotic and/or
necrotic (AnnV+PI+ cells) and necrotic (AnnV−PI+ cells). Cells that are negative
for AnnV-FITC and PI were recorded as live and healthy. Flow cytometric data
was analysed using FlowJo v.10.0.7 (FlowJo).
The CellEvent Caspase-3/7 Green Probe Reagent (Life Technologies) was
used to stain murine monocytes on day 1 of the assays following the
manufacturer’s instructions.

In vivo β-glucan stimulation experiments and challenge with LPS
Following the schedules described in Figure 5a, mice were injected intraperitoneally with two doses of 400 μl of a suspension of β-glucan in PBS or 400 μl
of PBS (control mice). The concentration of β-glucan was adjusted so that mice
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